Popular terms

[SEARCH]

Rheumatoid Arthritis topics
Rheumatoid Arthritis
Osteoarthritis
Autoimmune
Multiple Sclerosis
Immune Disease
Autoimmune Disease
Antibodies
Astaxanthin
Hyaluronate
Hyaluronic Acid
Joint Pain
Hyaluronan
Immune Diseases
Autoimmune Diseases
Lung Cancer

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Rheumatoid Arthritis patents



      
           
This page is updated frequently with new Rheumatoid Arthritis-related patent applications. Subscribe to the Rheumatoid Arthritis RSS feed to automatically get the update: related Rheumatoid RSS feeds. RSS updates for this page: Rheumatoid Arthritis RSS RSS



Date/App# patent app List of recent Rheumatoid Arthritis-related patents
07/23/15
20150203537 
 Inhibition of gliadin peptides patent thumbnailnew patent Inhibition of gliadin peptides
Novel compounds and methods for the inhibition of biological barrier permeability and for the inhibition of peptide translocation across biological barriers are identified. Assays for determining modulators of biological barrier permeability and for peptide translocation across biological barriers are provided.
Alba Therapeutics Corporation


07/16/15
20150198609 
 Human autoantibodies specific for pad3 which are cross-reactive with pad4 and their use in the diagnosis and treatment of rheumatoid arthritis and related diseases patent thumbnailHuman autoantibodies specific for pad3 which are cross-reactive with pad4 and their use in the diagnosis and treatment of rheumatoid arthritis and related diseases
In one or more embodiments, the present invention provides a novel biomarker which provides a link between a distinct clinical phenotype and a biochemical effect of an autoantibody on an enzyme implicated in disease pathogenesis. In particular, the present invention provides an isolated or purified human autoantibody to pad3 protein.
The Johns Hopkins University


07/09/15
20150191461 
 Pyrazolyl derivatives as syk inhibitors patent thumbnailPyrazolyl derivatives as syk inhibitors
The present invention provides novel pyrazole derivatives of formula i which are potent inhibitors of spleen tyrosine kinase, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, copd, rheumatoid arthritis, and cancer.. .
Merck Sharp & Dohme Corp.


07/09/15
20150191455 
 Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto patent thumbnailPyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto
Pyrazole derivatives of formula ia and pharmaceutical compositions thereof that modulate the activity of the pgi2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (pah) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (sle); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (copd)..
Arena Pharmaceuticals, Inc.


07/09/15
20150191454 
 Modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto patent thumbnailModulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto
Cyclohexane derivatives of formula ia and pharmaceutical compositions thereof that modulate the activity of the pgi2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (pah) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (sle); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (copd)..

07/09/15
20150190433 
 Treatment of inflammatory diseases using placental stem cells patent thumbnailTreatment of inflammatory diseases using placental stem cells
Provided herein are methods of treatment of individuals having an immune-related disease, disorder or condition, for example, inflammatory bowel disease, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis, psoriasis, lupus erythematosus, diabetes, mycosis fungoides (alibert-bazin syndrome), or scleroderma using placental stem cells or umbilical cord stem cells.. .
Anthrogenesis Corporation


07/09/15
20150190351 
 Compounds with (1e, 6e)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof patent thumbnailCompounds with (1e, 6e)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof
The present invention includes compounds, pharmaceuticals and cosmetics having at least one (substituted phenyl)-propenal moiety. The compounds and compositions of the present invention are useful in the treatment or prevention of medical conditions including androgen associated conditions, androgen associated inflammation, a wound (the compounds assist with wound healing), acne, rheumatoid arthritis, psoriasis, rosacea, and alopecia; kennedy's disease (spinal and bulbar muscular atrophy, or sbma), polyglutamine-mediated motor neuron degeneration; cancers such as prostate cancer, bladder cancer, breast cancer, ovarian cancer, hepatocellular (liver) cancer, and pancreatic cancer; and other medical conditions described herein.

07/02/15
20150183859 
 Anti-c5a antibodies and methods for using the antibodies patent thumbnailAnti-c5a antibodies and methods for using the antibodies
The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to c5a and to use of the antibodies in methods for treating or preventing complement-associated disorders such as, but not limited to, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burn, antiphospho lipid syndrome, asthma, lupus nephritis, goodpasture's syndrome, and chronic obstructive pulmonary disease.. .
Alexion Pharmaceuticals, Inc.


06/25/15
20150175978 
 Composition for preventing or treating rheumatoid arthritis patent thumbnailComposition for preventing or treating rheumatoid arthritis
The present disclosure relates to a composition for treating and preventing an rheumatoid arthritis, wherein the composition containing a peptide comprising amino acid sequence of seq id no: 1, a peptide having 80% or more sequence identity with the amino acid sequence of the peptide or a peptide which is a fragment thereof. According to the present invention, provided is a composition for prevention or treatment of rheumatoid arthritis having a.
Kael-gemvax Co., Ltd.


06/25/15
20150175710 
 Alpha-enolase specific antibodies and  use in immune diseases patent thumbnailAlpha-enolase specific antibodies and use in immune diseases
A method for treating an inflammatory disease or an immune disorder includes administering to a subject in need of such treatment an antagonist against eno1. The antagonist binds eno1 and inhibits eno1 plasminogen receptor activity.
Development Center For Biotechnology


06/25/15
20150175693 

Novel il-3 antibodies and their use in diagnosis and treatment of diseases or malfunctions associated with elevated levels of il-3


Novel anti-il-3 antibodies or fragments or constructs thereof according to the present invention specifically bind to an epitope contained within the n-terminal 20 amino acids of the amino acid sequence of human il-3 according to seq id no. 1, and preferably to a sequence motif swvn.
Universitatsklinikum Regensburg


06/25/15
20150175692 

Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders


The present disclosure relates to antibodies and proteins comprising an antigen-binding portion thereof that specifically bind to the pro-inflammatory cytokine il-17a. The disclosure more specifically relates to specific antibodies and proteins that are il-17a antagonists (inhibit the activities of il-17a and il-17af) and are capable of inhibiting il-17a induced cytokine production in in vitro assays, and having an inhibitory effect in an antigen-induced arthritis model in vivo.
Novartis Ag


06/25/15
20150175600 

2-(azaindol-2-yl)benzimidazoles as pad4 inhibitors


And salts thereof are pad4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, and psoriasis.. .

06/25/15
20150175575 

Imidazolyl analogs as syk inhibitors


The present invention provides novel imidazole analogs of formula i which are potent inhibitors of spleen tyrosine kinase, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, copd, rheumatoid arthritis, and cancer.. .
Merck Canada Inc.


06/18/15
20150166547 

Compounds and methods for kinase modulation, and indications therefor


Compounds and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof are active on at least one of fms protein kinase or kit protein kinase.
Plexxikon Inc.


06/18/15
20150164912 

Furo[3, 2-b] pyrr0l-3-ones as cathespin s inhibitors


Compounds of formula (i) exhibit surprisingly high efficacies for human cathepsin s, excellent selectivity verses other mammalian cathepsins and are useful for treatment of diseases such as rheumatoid arthritis, multiple sclerosis, myasthenia gravis, transplant rejection, diabetes, sjogrens syndrome, grave's disease, systemic lupus erythematosis, osteoarthritis, psoriasis, idiopathic thrombocytopenic purpura, allergic rhinitis, asthma, atherosclerosis, obesity, chronic obstructive pulmonary disease and chronic pain.. .

06/18/15
20150164824 

Methods and compositions useful for improving bone and joint health


Compositions for improving bone health, joint health, or both in an individual in need thereof are provided, along with methods of using the compositions. Generally, the compositions include a combination of curcumin and vitamin k2.
Abbott Laboratories


06/11/15
20150160236 

Methods for determining anti-tnf therapeutic response


The present invention relates to methods for identifying patients that will respond to treatment with anti-tnf-therapy, i.e., anti-tnf responder patients. In particular, the present invention relates to determining response to an inhibitor of tumor necrosis factor (tnf) in a patient with a chronic inflammatory disease by determining the activity of type i interferon in the patient.
New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery


06/11/15
20150157678 

Feijoa fruit extract


The invention relates to a feijoa fruit extract. In particular the invention relates to therapeutic uses of a feijoa fruit extract, processes for preparing the extract, and compositions comprising the extract.
Southwest Scientific Editing & Consulting, L.l.c.


06/04/15
20150152178 

Il-17 antagonistic antibodies


An il-17 binding molecule, in particular .an antibody to human il-17, more preferably a human antibody to human il-17 is provided, wherein the hypervariable regions or the heavy and light chains have amino acid sequences as defined, for use in the treatment of an il-17 mediated disease or disorder, e.g. rheumatoid arthritis..
Novartis Ag


06/04/15
20150152138 

Uses of kappa opioid synthetic peptide amides


The invention relates to methods of use of synthetic peptide amides that are ligands of the kappa opioid receptor in the treatment and prevention of kappa opioid receptor-associated diseases and conditions; and particularly to uses of these agonists in the prophylaxis, inhibition and treatment of pain, inflammation and pruritis associated with a variety of diseases, disorders and conditions. Inflammatory conditions preventable or treatable by the methods of the invention include diseases and conditions associated with elevated levels of a proinflammatory cytokines, such as tnf-α, il-1β, il-6, mmp-1 and mmp-3.
Cara Therapeutics, Inc.


06/04/15
20150150969 

Chimeric and humanized anti-histone antibodies


The present invention concerns chimeric or humanized antibodies or antigen-binding fragments thereof that comprise specific cdr sequences, disclosed herein. Preferably, the antibodies or fragments comprise specific heavy and light chain variable region sequences disclosed herein.
Immunomedics, Inc.


06/04/15
20150150856 

Novel compounds useful for the treatment of degenerative and inflammatory diseases


The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, diseases involving cartilage degradation, bone and/or joint degradation, for example osteoarthritis; and/or conditions involving inflammation or immune responses, such as crohn's disease, rheumatoid arthritis, psoriasis, allergic airways disease (e.g. Asthma, rhinitis), juvenile idiopathic arthritis, colitis, inflammatory bowel diseases, endotoxin-driven disease states (e.g.

06/04/15
20150150458 

Imaging interfaces for full finger and full hand optical tomography


Joint imaging devices methods and systems provide multiple sources and detectors around small accessible joints, such as fingers, to permit optical tomographic image acquisition and diagnosis of medical conditions such as rheumatoid arthritis. In embodiments, transducers permit convenient arrangement of sources and detectors and the rapid acquisition of anatomical surface geometry..
The Trustees Of Columbia University In The City Of New York


05/28/15
20150148306 

Compositions and methods for the treatment of inflammation


The invention relates to the compounds of formula i or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula i, and methods for the treatment of inflammation may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection.

05/21/15
20150141472 

Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use


The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-phenyl-sulfonamido-cycloalkyl compounds of the following formula (collectively referred to herein as “apsac compounds”). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, in treatment, for example, of inflammation and/or joint destruction and/or bone loss; of disorders mediated by excessive and/or inappropriate and/or prolonged activation of the immune system; of inflammatory and autoimmune disorders, for example, rheumatoid arthritis, psoriasis, psoriatic arthritis, chronic obstructive pulmonary disease (copd), atherosclerosis, inflammatory bowel disease, ankylosing spondylitis, and the like; of disorders associated with bone loss, such as bone loss associated with excessive osteoclast activity in rheumatoid arthritis, osteoporosis, cancer-associated bone disease, paget's disease and the like, etc.; and of cancer, such as a haematological malignancy, a solid tumour, etc..
Pimco 2664 Limited


05/21/15
20150141451 

Compositions and methods for the treatment of chronic pain


The invention relates to the compounds of formula i and formula ii or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula i or formula ii, and methods for treating chronic pain in a disease may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection.
Cellixbio Private Limited


05/21/15
20150141409 

Novel revamipide prodrugs, preparation method and use thereof


Disclosed are a novel rebamipide prodrug, a method for preparing the same, and use thereof. Also, a pharmaceutical composition comprising the novel rebamipide prodrug as an active ingredient is provided.
Astech.co., Ltd.


05/21/15
20150141396 

Pyrimidine pyrazolyl derivatives


The present invention provides compounds of formula (i) for the treatment of cancer, rheumatoid arthritis and other diseases.. .
Ares Trading S.a.


05/21/15
20150139945 

Compositions and methods for immunomodulation in an organism


The present invention relates to a therapeutic polypeptide and methods for its creation and use for modulating an immune response in a host organism in need thereof. In particular, the invention relates to the administration to an organism in need thereof, of an effective amount of a pre-coupled polypeptide complex comprising a lymphokine polypeptide portion, for example il-15 (seq id no: 5, 6), il-2 (seq id no: 10, 12) or combinations of both, and an interleukin receptor polypeptide portion, for example il-15ra (seq id no: 7, 8), il-2ra (seq id no: 9, 11) or combinations of both, for augmenting the immune system in, for example, cancer, scid, aids, or vaccination; or inhibiting the immune system in, for example, rheumatoid arthritis, or lupus.
University Of Connecticut


05/14/15
20150133475 

Compositions and methods for the treatment of periodontitis and rheumatoid arthritis


The invention relates to the compounds of formula i or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula i, and methods for the treatment of periodontitis and rheumatoid arthritis may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection..

05/14/15
20150133408 

Compositions and methods for the treatment of restless leg syndrome and fibromyalgia


The invention relates to the compounds of formula i or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula i, and methods for the treatment of fibromyalgia, restless leg syndrome may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection.

05/14/15
20150133322 

Method for the diagnosis of early rheumatoid arthritis


The present invention relates to biomarkers that are specifically recognized by autoantibodies present in a biological of patients with rheumatoid arthritis (ra). The invention provides methods and kits using these biomarkers for the diagnosis of ra, in particular for the diagnosis of early ra..

05/14/15
20150132305 

Humanized antibodies targeting the ec1 domain of cadherin-11 and related compositions and methods


The present invention relates to humanized antibodies that specifically bind an ec1 domain of a mammalian cadherin-11 protein and compositions (e.g., pharmaceutical compositions) comprising such antibodies. The invention also relates to methods for treating cadherin-11-mediated disorders in a mammalian subject by administering a therapeutically effective amount of a humanized antibody of the invention.

05/07/15
20150126527 

Modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto


The present invention relates to amide derivatives of formula (xiiia) and pharmaceutical compositions thereof that modulate the activity of the pgi2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (pah); idiopathic pah; familial pah; pah associated with a collagen vascular disease, a congenital heart disease, portal hypertension, hiv infection, ingestion of a drug or toxin, hereditary hemorrhagic telangiectasia, splenectomy, pulmonary veno-occlusive disease (pvod) or pulmonary capillary hemangiomatosis (pch); pah with significant venous or capillary involvement; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack, angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (sle); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (copd)..

05/07/15
20150126493 

Bicyclic sulfone compounds for inhibition of rorgamma activity and the treatment of disease


The invention provides bicyclic sulfone compounds, pharmaceutical compositions, methods of inhibiting rory activity, reducing the amount of il-17 in a subject, and treating immune disorders and inflammatory disorders using such bicyclic sulfone compounds. Another aspect of the invention provides a method of treating a subject suffering from a medical disorder.
Lycera Corporation


05/07/15
20150125964 

Detection of diagnostic peptides


An assay for citrullinated fragments of socs-2, alpha 1 anti tyrpsin, versican, biglycan, laminin, or other protein having a terminal antibody binding site comprising citrulline in a blood derived sample shows diagnostic relevance in relation to rheumatoid arthritis or fibrotic disease.. .
Nordic Biosciences A/s


04/30/15
20150119452 

Compositions and methods for the treatment of neurological conditions


The invention relates to the compounds of formula i or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula i, and methods for the treatment of neurological conditions may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection.

04/30/15
20150119275 

Methods for diagnosing, staging, predicting risk for developing and identifying treatment responders for rheumatoid arthritis


Disclosed are methods for diagnosing, staging, and predicting risk for developing rheumatoid arthritis and other inflammatory diseases, and methods for identifying treatment responders and non-responders.. .
Singulex, Inc.


04/30/15
20150118711 

Humanized anti-il-20 antibody and uses thereof


Humanized antibodies specific to human interleukin 20 (il-20) and uses thereof in treating diseases associated with the il-20 signaling pathway, e.g., osteoporosis, inflammatory disease (e.g., rheumatoid arthritis), cancer, stroke, and renal failure.. .
National Cheng Kung University


04/30/15
20150118229 

Jak1 selective inhibitor and uses thereof


The invention relates to the use of a jak1 kinase-selective inhibitor that has minimal inhibitory activity towards jak2 kinase for treating a disease, such as an inflammatory disease (e.g., moderate to severe rheumatoid arthritis) and/or bone loss, either alone or in combination with a dmard (disease modifying anti-rheumatic drug), such as methotrexate. The invention also provides pharmaceutical composition, dosage formulation, administration route, and dosage schedule thereof..
Abbvie Inc.


04/23/15
20150111966 

Compositions and methods for the treatment of fibromyalgia pain


The invention relates to the compounds of formula i or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula i, and methods for the treatment of fibromyalgia pain may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection.

04/23/15
20150111870 

Quinolinyl modulators of roryt


The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating rorγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1..

04/16/15
20150105404 

Phenyl linked quinolinyl modulators of roryt


The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating rorγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1..

04/16/15
20150105372 

Secondary alcohol quinolinyl modulators of roryt


The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating rorγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1..

04/16/15
20150105369 

Alkyl linked quinolinyl modulators of roryt


The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating rorγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1..

04/16/15
20150105366 

Methylene linked quinolinyl modulators of roryt


The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating rorγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1..

04/16/15
20150105365 

Heteroaryl linked quinolinyl modulators of rorgammat


The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating rorγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1..

04/16/15
20150104450 

Ctla-4 variants


Variants of cytotoxic t-lymphocyte antigen 4 (ctla-4) with high affinity, potency and stability. Formulations of ctla-4 variants at high concentration for subcutaneous or intravenous administration, e.g.
Medimmune Limited


04/09/15
20150099787 

Non-flushing niacin analogues, and methods of use thereof


One aspect of the present invention relates to substituted pyridines and pharmaceutially acceptable salts thereof that are active against a range of mammalian maladies. Another aspect of the invention relates to a pharmaceutical composition, comprising a compound of the present invention or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient.
Trustees Of Tufts College


04/09/15
20150099001 

Nanocell drug delivery system


Nanocells allow the sequential delivery of two different therapeutic agents with different modes of action or different pharmacokinetics. A nanocell is formed by encapsulating a nanocore with a first agent inside a lipid vesicle containing a second agent.
Massachusetts Institute Of Technology


04/09/15
20150098993 

Compositions, process of preparation of said compositions and treating inflammatory diseases


The present invention describes a composition and a kit, each having a plurality of compounds, for use in the treatment of inflammatory joint diseases and chronic inflammatory connective tissue diseases, such as rheumatoid arthritis (ra). The invention also relates to a process of obtaining the composition and a method of treating diseases by administration of the compositions..

04/02/15
20150094337 

Heterocyclic group contained amino-methanol derivative, and salt, synthetic method and use thereof


The present invention provides a heterocyclic group contained amino-methanol derivative, and salt, a preparation method and use thereof, and belongs to the medical field. The heterocyclic group contained amino-methanol derivative and the salt thereof of the present invention are used for preparing medicines for immune suppression and for the treatment of organ transplant rejection, or medicines for treating immune mediated inflammatory diseases, such as multiple sclerosis, systemic lupus erythematosus and rheumatoid arthritis..
Beijing Foreland Biopharma Co., Ltd.


04/02/15
20150093357 

Compositions and methods for immunomodulation in an organism


The present invention relates to a therapeutic polypeptide and methods for its creation and use for modulating an immune response in a host organism in need thereof. In particular, the invention relates to the administration to an organism in need thereof, of an effective amount of a pre-coupled polypeptide complex comprising a lymphokine polypeptide portion, for example il-15 (seq id no: 5, 6), il-2 (seq id no: 10, 12) or combinations of both, and an interleukin receptor polypeptide portion, for example il-15ra (seq id no: 7, 8), il-2ra (seq id no: 9, 11) or combinations of both, for augmenting the immune system in, for example, cancer, scid, aids, or vaccination; or inhibiting the immune system in, for example, rheumatoid arthritis, or lupus.
University Of Connecticut


03/26/15
20150087674 

Compositions and methods for the treatment of severe pain


The invention relates to the compounds of formula i or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula i, and methods for the treatment of severe pain may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection.

03/26/15
20150087660 

Compositions and methods for the treatment of chronic diseases and inflammatory disorders


The invention relates to the compounds of formula i or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula i, and methods for the treatment of chronic diseases and inflammatory disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection.

03/26/15
20150087646 

Triazolone compounds as mpges-1 inhibitors


The present disclosure is directed to compounds of formula (i), and pharmaceutically acceptable salts thereof, as mpges-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin e synthase-1 (mpges-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases..
Glenmark Pharmaceuticals S.a.


03/26/15
20150087626 

Cyclic amine derivatives as ep4 receptor antagonists


The present invention therefore relates to novel compounds which are selective antagonists of the ep4 subtype of pge2 receptors with analgesic and antinflammatory activity, processes for their preparation, pharmaceutical compositions containing them and their use as medicaments, inter alia for the treatment or alleviation of prostaglandin e mediated diseases such as acute and chronic pain, osteoarthritis, inflammation-associated disorder as arthritis, rheumatoid arthritis, cancer, migraine and endometriosis.. .

03/26/15
20150087548 

Marker sequences for rheumatoid arthritis and use thereof


The present invention relates to new marker sequences for rheumatoid arthritis and the diagnostic use thereof together with a method for screening of potential active substances for rheumatoid arthritis by means of these marker sequences. Furthermore, the invention relates to a diagnostic device containing such marker sequences for rheumatoid arthritis, in particular a protein biochip and the use thereof..
Protagen Aktiengesellschaft


03/26/15
20150086556 

Anti-activin a antibodies and uses thereof


The disclosure provides compositions and methods relating to or derived from anti-activin a binding proteins, including antibodies. In particular embodiments, the disclosure provides fully human, humanized, and chimeric anti-activin a antibodies that bind human activin a, activin a-binding fragments and derivatives of such antibodies, and activin a-binding polypeptides comprising such fragments.
Amgen Inc.


03/19/15
20150080356 

Method for improving therapy for autoimmune diseases such as rheumatoid arthritis


In the present invention, a method using a combination of iguratimod or a salt thereof and one or more immunosuppressants is useful as a method for the treatment of autoimmune diseases, and with this method adverse effects are lessened. A pharmaceutical composition containing this combination is useful for the treatment of autoimmune diseases.
Toyama Chemical Co., Ltd.


03/19/15
20150080245 

Rheumatoid arthritis diagnosis kit


The present invention aims to diagnose rheumatoid arthritis more accurately and rapidly, and relates to a method and a kit for diagnosing rheumatoid arthritis, based on the detection of citrullinated autoantigens in a test sample.. .
Catholic University Industry-academic Cooperation Foundation


03/12/15
20150073030 

Tcr/mhcii-collagen interaction inhibitors useful for the treatment of rheumatoid arthritis


The t cells specific to human collagen type ii, one of the possible autoantigens, have a crucial role in the development of rheumatoid arthritis in the context of hla-dr4. The protein-protein interactions between the t cell receptor (tcr) and the type ii collagen linked to the allele mhc of class ii hla-dr4 may thus represent the target for the development of new drugs against rheumatoid arthritis.
UniversitÀ Cattolica Del Sacro Cuore


03/12/15
20150072980 

Substituted 2,3-dihydro-1h-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis


The present invention is directed to compounds, their synthesis, and their use as antagonists, inverse agonists, modulators and or inhibitors of the retinoic acid-related orphan nuclear receptor γt (rorγt)/rorγ. The compounds of the present invention are useful for modulating rorγt)/rorγ activity and for treating diseases or conditions mediated by rorγt)/rorγ such as for example, disease states associated with immunopathology of human autoimmune diseases such as multiple sclerosis (ms), rheumatoid arthritis (ra), inflammatory colitis, psoriasis, copd, pain, obesity, diabetes, dyslipidemia, osteoporosis, asthma, neurodegenerative diseases and cancer..
Arrien Pharmaceuticals Llc


03/05/15
20150064196 

Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof


These compounds are useful in the treatment, prevention, prophylaxis, management, or adjunct treatment of all medical conditions related to inhibition of bruton's tyrosine kinase (btk), such as inflammatory and/or autoimmune disorder, cell proliferation, rheumatoid arthritis, psoriasis, psoriatic arthritis, transplant rejection, graft-versus-host disease, multiple sclerosis, inflammatory bowel disease, allergic diseases, asthma, type 1 diabetes, myasthenia gravis, hematopoetic disfunction, b-cell malignancies, systemic lupus, erythematosus or other disorders.. .

03/05/15
20150064195 

Uses and compositions for treatment of rheumatoid arthritis


The invention provides methods, uses and compositions for the treatment of rheumatoid arthritis. The invention describes methods and uses for treating rheumatoid arthritis wherein a tnfα inhibitor, such as a human tnfα antibody, or antigen-binding portion thereof.

03/05/15
20150064194 

Uses and compositions for treatment of rheumatoid arthritis


The invention provides methods, uses and compositions for the treatment of rheumatoid arthritis. The invention describes methods and uses for treating rheumatoid arthritis wherein a tnfα inhibitor, such as a human tnfα antibody, or antigen-binding portion thereof.

03/05/15
20150064177 

Therapeutic uses of humanized antibodies against alpha-4 integrin


The invention provides methods of treatment using humanized immunoglobulins that specifically bind to alpha-4 integrin. The methods are useful for treatment of asthma, atherosclerosis, aids dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, transplant rejection, graft versus host disease, tumor metastasis, nephritis, atopic dermatitis, psoriasis, myocardial ischemia, and acute leukocyte mediated lung injury..
Biogen Idec Ma Inc.


03/05/15
20150064168 

Cadherin-11 inhibitors and methods of use thereof


Cadherin-11 inhibitors and methods for the prevention and treatment of cadherin-11 related diseases are described herein. Cadherin-11 related diseases include cancer and rheumatoid arthritis..
Georgetown University


03/05/15
20150064132 

Treatment methods for rheumatoid arthritis


The present invention provides methods for selecting treatment methods for rheumatoid arthritis based on an objective selection process (algorithm). The present invention also provides methods for treating rheumatoid arthritis with treatment methods selected based on the algorithm disclosed herein.



Popular terms: [SEARCH]

Rheumatoid Arthritis topics: Rheumatoid Arthritis, Osteoarthritis, Autoimmune, Multiple Sclerosis, Immune Disease, Autoimmune Disease, Antibodies, Astaxanthin, Hyaluronate, Hyaluronic Acid, Joint Pain, Hyaluronan, Immune Diseases, Autoimmune Diseases, Lung Cancer

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Rheumatoid Arthritis for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Rheumatoid Arthritis with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.4746

3973

0 - 1 - 71